Among participants in the REDUCE-IT trial of eicosapentaenoic acid (IPE) in patients with statin-controlled LDL-C and raised TG levels, Lp(a) was more strongly related to risk of major adverse cardiovascular events (MACE) on a per particle basis than non-Lp(a) apoB, report multinational triallists in a post hoc analysis of the study.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
